Skip to Content

Real-World Data on Avelumab as 1L Maintenance Treatment

In this MEDtalk, Dr. Philippe Barthelemy, from the ICANS Institute in Strasbourg, discusses the AVENANCE study results with real-world data from France. The study confirms the effectiveness and safety of avelumab as a safe standard of care for patients with advanced urothelial carcinoma.

Philippe Barthelemy

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top